伊马替尼治疗慢性髓系白血病的血药浓度研究进展
被引量：1
摘要
伊马替尼通过选择性地抑制bcr-abl融合蛋白的高酪氨酸激酶活性，成为第一个瞄准慢性髓系白血病（CML）致病原因的小分子靶向药物[1-2]最新伊马替尼国际随机研究（IRIS）[3]显示伊马替尼应用于CML慢性期患者，
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2012年第1期69-70,共2页
Chinese Journal of Hematology
参考文献17
-
1Savage DG,Antman KH.Imatinib mesylate-a new oral targeted therapy.N Engl J Med,2002,346:683-693.
-
2Druker BJ,Talpaz M,Resta DJ,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med,2001,344:1031-1037.
-
3Deininger M,O' Brien SG,Guilhot F,et al.International randomized study of interferon vs STI571 (IRIS) 8-year follow up:sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib.Blood,2009,114:Abstract 1126.
-
4Druker B J,Guilhot F,O' Brien SG,et al.Five-year follow-up of patients receiving imatinibfor chronic myeloid leukemia.N Engl J Med,2006,355:2408-2417.
-
5Hochhaus A,O' Brien SG,Guilhot F,et al.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia,2009,23:1054-1061.
-
6Apperley JF.Part Ⅰ:mechanisms of resistance to imatinib in chronic myeloid leukaemia.Lancet Oncol,2007,8:1018-1029.
-
7Peng BM,Hayes M,Resta D,et al.Pharmacokinetics and pharmacodynamics of imatinib in a phase Ⅰ trial with chronic myeloid leukemia patients.J Clin Oncol,2004,22:935-942.
-
8Peng B,Lloyd P,Schran H.Clinical pharmacokinetics of imatinib.Clin Pharmacokinet,2005,444:879-894.
-
9Picard S,Titier K,Etienne G,et al.Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.Blood,2007,109:3496-3499.
-
10Larson RA,Druker BJ,Guilhot F,et al.Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia:a subanalysis of the IRIS study.Blood,2008,111:4022-4028.
同被引文献2
-
1周励,孟凡义,金洁,曾庆曙,杜新,黄晓军,沈志祥.我国慢性髓系白血病患者服用伊马替尼血药浓度的初步分析[J].中华血液学杂志,2012,33(3):183-186. 被引量：5
-
2陈娟,周励,杜圣红,卢虹颖,孙舒君,李军民,赵维莅,沈志祥.国产伊马替尼治疗初发慢性髓性白血病的疗效与安全性观察[J].中华血液学杂志,2015,36(3):235-237. 被引量：9
二级引证文献2
-
1张淳嘉,吴爱玲,郑小玲,郑丹钿,夏维林.伊马替尼治疗慢性髓性白血病患者早期分子学反应的危险因素分析[J].临床合理用药杂志,2021,14(13):101-103.
-
2孔滢,刘红,彭洪薇,江学辉,邹德琴,肖雄,王峰,魏筱华.二维液相色谱法同时测定人血浆中伊马替尼及去甲伊马替尼药物浓度及临床应用[J].中国现代应用药学,2022,39(17):2229-2235. 被引量：4
-
1徐敏,朱美琴,白桦,陈亦欣,申维玺.伊立替康联合替吉奥改良化疗方案治疗转移性结直肠癌的效果[J].广东医学,2015,36(9):1421-1423. 被引量：7
-
2吴英理,邬维礼,孙关林.甲异靛对K562细胞的作用及其机制的初步研究[J].中华血液学杂志,2004,25(1):43-45. 被引量：10
-
3程子芸,赵建飞,丁艺,丁玲,周怀君.小分子靶向药物在子宫内膜癌中的临床研究进展[J].东南大学学报（医学版）,2016,35(5):817-820. 被引量：2
-
4刘定胜,李玉峰,曹维克,陈侃侃,陈凤丽,刘小宁,丁邦和,朱家斌,何正梅.塞来昔布对K562细胞BCR-ABL融合蛋白及下游增殖信号转导途径的影响[J].中华血液学杂志,2010,31(6):407-409. 被引量：3
-
5印彤.慢性粒细胞白血病的治疗进展[J].国外医学（输血及血液学分册）,2004,27(4):349-351. 被引量：4
-
6徐敏,朱美琴,白桦,陈亦欣,申维玺.伊立替康联合替吉奥改良化疗方案与FOLFIRI治疗晚期结直肠癌的疗效对比观察[J].医学临床研究,2015,32(7):1296-1298. 被引量：1
-
7周冬梅,韩正祥,杜秀平,孔静姝,王红梅.替吉奥联合伊立替康治疗FOLFOX耐药的晚期结直肠癌的临床研究[J].肿瘤药学,2014,4(5):350-353. 被引量：5
-
8陈珊珊.酪氨酸激酶抑制剂与慢性髓系白血病干细胞[J].中华血液学杂志,2011,32(7):492-496. 被引量：1
-
9安艳新,王菁,刘家良,吉棚,张小桥.进展期胃癌靶向治疗的研究进展[J].现代生物医学进展,2013,13(21):4197-4200. 被引量：4
-
10严匡华,卞寿庚.p190慢性粒细胞白血病研究进展[J].中华血液学杂志,2003,24(6):332-334. 被引量：11
